The latest price target for Cytek Biosciences (NASDAQ:CTKB) was reported by TD Cowen on January 8, 2026. The analyst firm set a price target for $5.00 expecting CTKB to rise to within 12 months (a possible 17.65% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Cytek Biosciences (NASDAQ:CTKB) was provided by TD Cowen, and Cytek Biosciences maintained their buy rating.

There is no last upgrade for Cytek Biosciences

The last downgrade for Cytek Biosciences Inc happened on January 31, 2025 when Goldman Sachs changed their price target from $7 to $4.5 for Cytek Biosciences Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cytek Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cytek Biosciences was filed on January 8, 2026 so you should expect the next rating to be made available sometime around January 8, 2027.

While ratings are subjective and will change, the latest Cytek Biosciences (CTKB) rating was a maintained with a price target of $4.00 to $5.00. The current price Cytek Biosciences (CTKB) is trading at is $4.25, which is within the analyst’s predicted range.